CMV Prophylaxis During Kidney Transplant Rejection

Primary Recommendation

The KDIGO guidelines recommend that kidney transplant recipients receive 6 weeks of CMV chemoprophylaxis after treatment with a T-cell-depleting antibody, regardless of their baseline CMV serostatus, with a Grade 1C recommendation indicating strong evidence supporting this practice 1, 2, 3
Kidney transplant patients undergoing treatment for acute rejection should receive CMV prophylaxis with valganciclovir for 6 weeks following T-cell-depleting antibody therapy, as recommended by the KDIGO guidelines 1, 2, 3

Administer oral valganciclovir 900 mg daily (adjusted for renal function) for 6 weeks following completion of T-cell-depleting antibody therapy for rejection, as recommended by the KDIGO guidelines 1, 2, 3
Start prophylaxis immediately upon initiation of rejection treatment, as recommended by the KDIGO guidelines 1

Perform weekly CMV monitoring by quantitative plasma NAT or pp65 antigenemia during active CMV disease or high-risk periods, as recommended by the KDIGO guidelines 1, 2
Screen for BK virus reactivation after rejection treatment, as immunosuppression reduction and augmentation both affect BK virus risk, according to the KDIGO guidelines 3, 4

Monitor graft function closely during CMV prophylaxis to detect early signs of ongoing rejection that may require additional intervention, as recommended by the KDIGO guidelines 1, 2
If life-threatening CMV disease develops despite prophylaxis, consider reducing immunosuppressive medications until CMV disease resolves, while balancing rejection risk, as recommended by the KDIGO guidelines 1, 2

Do not omit prophylaxis based on CMV serostatus alone, as even CMV R+ patients benefit from prophylaxis after T-cell depletion, according to the KDIGO guidelines 1, 2